Tandem Diabetes Care, Inc. (TNDM)
| Market Cap | 1.28B |
| Revenue (ttm) | 1.01B |
| Net Income (ttm) | -204.71M |
| Shares Out | 68.50M |
| EPS (ttm) | -3.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,489,748 |
| Open | 19.86 |
| Previous Close | 19.82 |
| Day's Range | 18.58 - 20.08 |
| 52-Week Range | 9.98 - 29.65 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 28.00 (+50.3%) |
| Earnings Date | May 7, 2026 |
About TNDM
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a pe... [Read more]
Financial Performance
In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price target is $28.0, which is an increase of 50.30% from the latest price.
News
Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type 1 diabetes.
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial m...
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. , (“ Tandem " or the "Company") ( NASDAQ:TNDM) investors that the firm has initiated an investi...
Tandem Diabetes Care Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Management outlined rapid progress in shifting to the pharmacy channel, driving record gross margins and projecting further gains as pharmacy sales grow. Product launches, including Mobi tubeless and Sigi, will address both tubed and tubeless market segments, while international expansion and technology integration remain key priorities.
Bullish Call On Tandem Diabetes Signals Long-Term Growth Confidence
Tandem Diabetes Care Inc. (NASDAQ: TNDM) stock is trading higher on Tuesday following an analyst upgrade, citing a long-term upside opportunity.
Tandem Mobi Now Compatible with Android Smartphones
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smalle...
Tandem Diabetes Care Transcript: TD Cowen 46th Annual Health Care Conference
The business is undergoing a strategic transformation with a shift to a PAYGO model, expanded pharmacy access, and a robust innovation pipeline including Mobi Tubeless and a fully closed loop algorithm. These initiatives are expected to drive double-digit growth, higher margins, and improved patient access.
Tandem Diabetes Care Transcript: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day
Record Q4 performance was driven by commercial transformation, new product launches, and a strategic shift to the pharmacy channel. The transition to direct sales internationally and a pay-as-you-go model in the U.S. is expected to drive recurring revenue and margin expansion, with significant growth projected for 2027.
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amou...
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions...
Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.
Tandem Diabetes Care Analysts Boost Their Forecasts After Upbeat Q4 Results
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported better-than-expected fourth-quarter financial results on Thursday.
Tandem Diabetes Care Earnings Call Transcript: Q4 2025
Achieved record 2025 results with over $1B in sales, double-digit growth, and margin expansion. 2026 guidance reflects a strategic shift to a pay-as-you-go pharmacy model, expected to drive long-term growth despite near-term headwinds, with new product launches and international expansion planned.
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year e...
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the ...
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2025 results after ...
Tandem t:slim Mobile App Now Available in Canada
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem t:slim mobile application is now available for Android and iOS users in Canada.
Tandem Diabetes Care Transcript: Piper Sandler 37th Annual Healthcare Conference
Significant Q3 revenue growth was driven by pharmacy channel expansion and pricing, with gross margins improving and a multi-year tailwind expected from further adoption. Product innovation, including a new patch pump and closed-loop system, positions the company for continued growth and market expansion.
Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to...
Tandem Diabetes Care Transcript: Stifel 2025 Healthcare Conference
Q3 2025 results met expectations, with strong pricing and pharmacy channel growth. The pipeline is robust, with tubeless Mobi and fully closed loop systems targeted for 2026. Type-2 and international markets offer significant expansion, and financial outlook includes margin and OPEX leverage improvements.
Tandem Mobi Receives FDA Clearance for Use with Android Smartphones
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administ...
Tandem Diabetes Care Earnings Call Transcript: Q3 2025
Record Q3 sales and margin improvements were driven by higher pricing, pharmacy channel expansion, and strong international growth. Strategic initiatives in innovation, direct sales, and operational efficiency position the business for double-digit growth and margin expansion in 2025 and beyond.
Tandem Diabetes Care Announces Third Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 3...
Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Global Data Security Standards
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC 27001:2022 Cert...
t:slim X2™ Insulin Pump Now Available with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring...